Progenics (PGNX), Salix (SLXP) Shares Higher Ahead of PDUFA Ruling for Relistor
Tweet Send to a Friend
Up)
Pharma investors are dipping a toe in shares of Progenics Pharma (Nasdaq: PGNX) and Salix Pharma (Nasdaq: SLXP) ahead of the PDUFA ruling for Relistor later this afternoon. While Progenics shares are up 2.2 percent to $10.84, shares of Salix are up 3.3 percent to $53.42.
One April 25th, the FDA extended the PDUFA goal date for the review of the sNDA for Relistor from April 25th to July 27th.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
One April 25th, the FDA extended the PDUFA goal date for the review of the sNDA for Relistor from April 25th to July 27th.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Salix Pharma (SLXP) Reports Positive Results From Two Budesonide Foam Phase 3s
- Echo Therapeutics (ECTE) Gets IRB Approval for Symphony CGM System
- Clearwire (CLWR) Approves Higher Sprint (S) Bid of $3.40/Share
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
